Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology.
The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies.
Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 24 | -0.44 Increased by +20.00% | -0.42 Decreased by -4.71% |
| Aug 8, 24 | -0.46 Increased by +2.13% | -0.39 Decreased by -18.86% |
| May 10, 24 | -0.44 Increased by 0.00% | -0.47 Increased by +6.38% |
| Mar 1, 24 | -0.72 Decreased by -28.57% | -0.51 Decreased by -41.18% |
| Nov 3, 23 | -0.55 Increased by +24.66% | -0.46 Decreased by -19.57% |
| Aug 7, 23 | -0.47 Decreased by -46.87% | -0.42 Decreased by -11.90% |
| May 11, 23 | -0.44 Decreased by -83.33% | -0.41 Decreased by -7.32% |
| Mar 9, 23 | -0.56 | -0.65 Increased by +13.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 209.00 K Increased by +N/A% | -52.52 M Decreased by -3.57% | Decreased by -25.13 K% Decreased by N/A% |
| Jun 30, 24 | 37.77 M Increased by +N/A% | -55.33 M Decreased by -30.53% | Decreased by -146.47% Decreased by N/A% |
| Mar 31, 24 | 591.00 K Increased by +N/A% | -45.76 M Decreased by -16.15% | Decreased by -7.74 K% Decreased by N/A% |
| Dec 31, 23 | 25.69 M Increased by +393.13% | -65.64 M Decreased by -67.10% | Decreased by -255.50% Increased by +66.11% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -50.71 M Decreased by -72.77% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -42.38 M Decreased by -44.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -39.40 M Decreased by -65.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 5.21 M Increased by +N/A% | -39.28 M Increased by +37.56% | Decreased by -753.99% Decreased by N/A% |